中文摘要：

目的：探讨复制缺陷型腺病毒载体（Ad）介导人血管内皮细胞生长因子受体-2（hVEGFR-2或hKDR）胞外段诱导抗小鼠肝癌血管免疫及打破免疫耐受的效果。方法：构建Ad hKDRE,用Ad hKDRE皮内免疫C57BL/6小鼠,7d后取脾细胞作为效应细胞（E）,Hepa1-6/mKDR作为靶细胞（T）,行乳酸脱氢酶（LDH）释放实验检测特异性CTL杀伤活性;给免疫小鼠接种肝癌细胞Hepa1-6,观察荷瘤小鼠成活情况。结果：Ad hKDRE免疫小鼠1周后,在E∶T为100∶1、50∶1和25∶1时,Ad hKDRE诱导的6hCTL杀伤率分别为（81.5±5.6）%、（68.4±5.5）%和（39.6±3.9）%。Ad hKDRE免疫小鼠1周后接种2×10^6 Hepa1-6肝癌细胞,观察2个月无小鼠成瘤;接种5×106 Hepa1-6细胞,小鼠无瘤成活率为60%。上述CTL效应和抗成瘤作用在清除CD8＋和CD4＋ T淋巴细胞后消失。结论：Ad介导异种（人）KDR胞外段能有效地打破小鼠肝癌的免疫耐受,诱发强烈的抗原特异性细胞免疫反应,这种特异性细胞免疫反应是CD4^＋和CD8^＋ T细胞依赖性的。

英文摘要：

Objective： To investigate the role of replication-defective adenovirus vector encodinG human extracellular domain of vascular endothelial growth factor receptor-2 （ hVEGFR-2 or hKDR） in induction of immunity against murine hepatocellular carcinomas and in breaking the immune tolerance. Methods： Ad hKDRE were constructed and were used to immunize C57BL/6 mice. Seven days after immunization mice splenocytes were collected as effectors and Hepa 1-6/mKDR cells were used as target cells for lactate dehydrogenase （LDH） release assay to analyze the cytotoxic ac- tivity of antigen-specific cytotoxic T lymphocytes （CTL）. In addition, immunized mice were transplanted with Hepa 1-6 cells and the survival of tumor-bearing mice was observed. Results： Seven days after the immunization, 6 h cytotoxic activity of CTL elicited by the Ad hKDRE were （81.5 ±5.6） % , （68.4 ± 5.5） % , and （39.6 ±3.9） % at the ratio of effector： target （E： T） of 100： 1,50： 1, and 25： 1, respectively. In addition, no tumor formed 2 months after implantation of 2 × 10^6hepatoma cells in Ad hKDRv-immunized mice ; after implantation of 5 × 10^6 hepatoma cells, 60% of the mice survived without bearing tumor. The above CTL activity and protection against tumor disappeared when CD8^＋ and CD4^＋ T lymphocytes were depleted from mice. Conclusion： Adenovirus vector-medlated xenogeneic extracellular domain of KDR can effectively break the immune tolerance to murine hepatocellular carcinomas in mice and induce a strong antigen- specific T cell response, which is dependent on CD8^＋ and CD4^＋ T cells.